Abstract
Emerging evidence suggests BRCA1/2 or ATM gene mutation status in metastatic pancreatic cancer (mPC) could predict clinical benefit from platinum-based chemotherapy and targeted therapies. We examined treatment patterns by BRCA 1/2/ATM mutation status in patients with mPC receiving routine care in the United States.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
